ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025
Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RSV vaccine development: advances and fusion protein-focused strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) can cause severe lower respiratory tract infections in infants and the elderly. Previously, most RSV vaccine antigen design strategies have focused on the stability of the prefusion (PreF) protein trimer conformation. We hypothesized that the RSV monomer might serve as a vaccine candidate immunogen. Here, we constructed an immunofocusing-based RSV F protein Q74 truncated monomer by truncating the RSV F protein and retaining only the head and neck regions. The structural prediction and protein antigenicity characterization of Q74 truncated monomer both indicated that it could bind to the antigenic site Ø-specific antibody D25, suggesting that this immunogen retained the structural features of PreF. In addition, the Q74 truncated monomer not only induced neutralizing and binding antibodies with a strength comparable to that of DS-Cav1 but also focused the immune response on antigenic site Ø and site II. In summary, we found that the RSV F protein monomer designed based on immunofocusing could induce relative immunogenicity and immune protection, providing a design strategy for RSV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.